Home > Publications > Medical Specialty > Internal Medicine > Haematology > Lymphoma & Leukaemia > EHA Congress 2024 Conference Review focus on Lymphoma & Leukaemia
EHA Congress 2024 Conference Review focus on Lymphoma & Leukaemia

EHA Congress 2024 Conference Review focus on Lymphoma & Leukaemia

In this edition:

Mosunetuzumab in high-risk, heavily pre-treated RR-FL
Axicabtagene ciloleucel for RR-PMBCL
SEQUOIA: zanubrutinib + venetoclax for treatment-naïve CLL/SLL with del(17P) and/or TP53 alterations
ASC4FIRST: asciminib vs. TKIs in newly diagnosed CML
PhALLCON: in-depth responder subgroup analysis
AUGMENT-101: revumenib monotherapy in relapsed/refractory KMT2A-rearranged acute leukaemia
IMROZ: isatuximab + VRd in transplant-ineligible, newly diagnosed multiple myeloma
JAK2V617F molecular response & EFS in early polycythaemia vera
Auto- vs. allo-SCT in T-cell lymphoma
HD21: BrECADD vs. BEACOPP for advanced-stage classical Hodgkin lymphoma

You need to be logged in to access this content.

Latest Publications and Videos

Stay up to date with our latest clinical information.

Explore Research Review Publications and Videos

Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry. 

Find Reviews in Your Clinical Area
Please select your country of practice.

It looks like you are closest to our New Zealand site.

Terms and Conditions

Website terms of use 

By using our website, you agree to follow these terms and conditions. 

 

Privacy policy 

We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms. 

 

Copyright and use of website content 

The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use. 

You cannot:  copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission. 

 

Links to third-party websites 

The Research Review website may link to third-party websites for your convenience. However: 

We do not endorse or approve their products, services, or actions. 

We are not responsible for their content or how they operate. 

There is no formal partnership between us and third parties unless we clearly state otherwise. 

 

Disclaimer and limitation of liability 

We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date. 

To the fullest extent allowed by law, we are not responsible for: 

Any loss, damage, or costs you may suffer from using (or being unable to use) our website. 

Any decisions you make based on the information provided. 

Any business losses, such as lost profits, lost data, or business interruptions. 

 

Governing law 

These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.